Arovella’s CEO and MD, Dr Michael Baker, will present data describing the key benefits of Arovella’s proprietary iNKT cell therapy platform as truly “off-the-shelf” with the potential for improved efficacy across a range of oncology indications. Highlights from the presentation include:
The “off-the-shelf” capabilities of Arovella’s CAR-iNKT platform
Potential benefits of CAR-iNKT cells over CAR-T in treating cancers
Key advantages of Arovella’s proprietary manufacturing process
The history of iNKT cells as a novel cell type and CAR-iNKT cells as a new treatment opportunity
The potential of ALA-101 in combination with Imugene’s onCARlytics platform to treat solid tumours
The possibility of Arovella’s proprietary iNKT cell platform with novel CARs to target solid tumours
